Early Discontinuation of Empirical Antifungal Therapy and Biomarkers
Impact of the Use of Biomarkers on Early Discontinuation of Empirical Antifungal Therapy in Critically Ill Patients: a Randomized Controlled Study.
University Hospital, Lille
194 participants
Jun 6, 2018
INTERVENTIONAL
Conditions
Summary
Empirical antifungal therapy (EAT) is frequently prescribed to septic critically ill patients with risk factors for invasive Candida infections (ICI). However, among patients without subsequent proven ICI, antifungal discontinuation is rarely performed, resulting in unnecessary antifungal overuse. The investigators postulate that the use of fungal biomarkers could increase the percentage of early discontinuation of EAT among critically ill patients suspected of ICI, as compared with a standard strategy, without negative impact on day 28-mortality. To test this hypothesis, the investigators designed a randomized controlled open-label parallel-group study.
Eligibility
Inclusion Criteria4
- Patient older than 18 years
- Who require EAT for the first time in the ICU (this treatment is prescribed based on the presence of risk factors and clinical suspicion of ICI)
- With an expected ICU length of stay of at least 6 days after EAT initiation
- Informed written consent
Exclusion Criteria6
- Neutropenia (neutrophil count <500 cells /µL)
- Active malignant hemopathy
- Bone marrow transplantation in the last 6 months
- Polyvalent immunoglobulins in the past months
- Documented ICI in the past 3 months
- Pregnancy or breastfeeding
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
EAT duration is determined by β-D-1,3-glucan and mannan serum assays, performed at day 0 (day of EAT initiation) and day 3.
EAT duration is based on IDSA guidelines, which recommend 14 days of treatment for patients without subsequent proven ICI, and who improve under antifungal treatment, or less in other situations.
Locations(10)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03538912